Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	AxoGen	Natus Medical	TransMedics Group	Semler Scientific	ViewRay
Symbol	NASDAQ:AXGN	NASDAQ:NTUS	NASDAQ:TMDX	OTCMKTS:SMLR	NASDAQ:VRAY
Price Information
Current Price	$19.34	$26.73	$28.96	$110.00	$4.57
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.5	1.1	1.6	1.2	1.3
Analysis Score	2.3	0.0	3.3	1.5	1.3
Community Score	2.9	1.9	2.3	2.5	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.0	1.7
Earnings & Valuation Score	0.6	1.9	0.6	1.9	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$23.75	N/A	$44.20	$110.50	$4.50
% Upside from Price Target	22.80% upside	N/A	52.62% upside	0.45% upside	-1.53% downside
Trade Information
Market Cap	$785.68 million	$904.78 million	$776.76 million	$738.87 million	$717.17 million
Beta	0.71	0.72	2.16	1.11	0.64
Average Volume	240,577	186,428	808,611	18,752	1,990,863
Sales & Book Value
Annual Revenue	$106.71 million	$495.52 million	$23.60 million	$32.77 million	$87.78 million
Price / Sales	7.39	1.83	33.90	22.55	8.37
Cashflow	N/A	$2.28 per share	N/A	$3.15 per share	N/A
Price / Cash	N/A	11.73	N/A	34.91	N/A
Book Value	$3.35 per share	$12.21 per share	$2.58 per share	$2.00 per share	$1.47 per share
Price / Book	5.77	2.19	11.22	55.00	3.11
Profitability
Net Income	$-29,140,000.00	$-15,670,000.00	$-33,550,000.00	$15.08 million	$-120,200,000.00
EPS	($0.68)	$1.24	($2.36)	$1.88	($1.18)
Trailing P/E Ratio	N/A	N/A	N/A	77.46	N/A
Forward P/E Ratio	N/A	23.65	N/A	48.46	N/A
P/E Growth	N/A	N/A	N/A	1.48	N/A
Net Margins	-22.98%	-4.33%	-131.35%	32.08%	-166.74%
Return on Equity (ROE)	-19.83%	3.87%	-38.95%	67.38%	-63.41%
Return on Assets (ROA)	-14.88%	2.50%	-24.10%	52.42%	-36.34%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.42%	0.06%	0.32%	N/A	0.26%
Current Ratio	7.45%	2.02%	11.31%	3.85%	3.90%
Quick Ratio	6.81%	1.41%	10.36%	3.85%	3.19%
Ownership Information
Institutional Ownership Percentage	78.38%	89.67%	76.68%	12.13%	83.03%
Insider Ownership Percentage	6.94%	1.50%	13.10%	13.60%	15.48%
Miscellaneous
Employees	346	1,484	110	86	236
Shares Outstanding	40.77 million	33.87 million	27.62 million	6.72 million	160.80 million
Next Earnings Date	5/5/2021 (Confirmed)	5/6/2021 (Confirmed)	5/4/2021 (Confirmed)	5/3/2021 (Estimated)	5/6/2021 (Confirmed)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Radiotherapy Market Opportunity, Challenges, Future Demands and Forecast by 2027: Covid-19 Impact and Recovery – Northern Gwinnett News - Northern Gwinnett News (NGwinnett.com) ngwinnett.com - April 22 at 1:41 PM
	ViewRay, Inc. (NASDAQ:VRAY): The Stock for Success Over the Next Few Months marketingsentinel.com - April 22 at 8:41 AM
	Zacks: Analysts Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Post Quarterly Sales of $13.49 Million americanbankingnews.com - April 22 at 3:38 AM
	Stock Traders Purchase Large Volume of Call Options on ViewRay (NASDAQ:VRAY) americanbankingnews.com - April 21 at 3:42 PM
	ViewRay (NASDAQ:VRAY) Trading 7.4% Higher americanbankingnews.com - April 21 at 12:58 PM
	Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) to Announce -$0.17 Earnings Per Share americanbankingnews.com - April 20 at 6:14 AM
	ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021 - PRNewswire prnewswire.com - April 19 at 7:28 PM
	ViewRay Announces Conference Call for First Quarter 2021 Financial Results to be Held After Market on May 6, 2021 finance.yahoo.com - April 19 at 7:28 PM
	ViewRay (NASDAQ:VRAY) Trading Down 3.9% americanbankingnews.com - April 19 at 12:46 PM
	ViewRay, Inc. (NASDAQ:VRAY) Given Consensus Rating of "Buy" by Brokerages americanbankingnews.com - April 12 at 8:50 AM
	Radiotherapy Market 2021 Highlights Recent Trends, Market Growth and Business Opportunities till 2027 – ROUGH Magazine - ROUGH Magazine rough.asia - April 9 at 6:25 PM
	AtriCure Names B. Kristine Johnson Board Chair - StreetInsider.com streetinsider.com - April 8 at 9:26 AM
	Zacks: Brokerages Anticipate ViewRay, Inc. (NASDAQ:VRAY) Will Announce Quarterly Sales of $13.49 Million americanbankingnews.com - April 4 at 1:40 AM
	Zacks: Brokerages Expect ViewRay, Inc. (NASDAQ:VRAY) Will Post Earnings of -$0.17 Per Share americanbankingnews.com - April 2 at 8:14 PM
	ViewRay (NASDAQ:VRAY) Stock Rating Upgraded by BTIG Research americanbankingnews.com - April 1 at 10:12 AM
	Should You Buy Viewray Inc (VRAY) Stock Friday Morning? - InvestorsObserver investorsobserver.com - March 27 at 1:06 AM
	ViewRay initiated buy at BTIG on management remarks - Seeking Alpha seekingalpha.com - March 27 at 1:06 AM
	New partnership enables access to state-of-the-art radiotherapy machine in Oxford - Mirage News miragenews.com - March 25 at 1:39 PM
	ViewRay Inc.'s chief operating officer is leaving the company - Crain's Cleveland Business crainscleveland.com - March 17 at 7:54 AM
	If You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain Today - Yahoo Finance finance.yahoo.com - March 16 at 3:11 PM
	If You Had Bought ViewRay (NASDAQ:VRAY) Stock A Year Ago, You Could Pocket A 224% Gain Today finance.yahoo.com - March 16 at 3:11 PM
	ViewRay Announces Departure of Chief Operating Officer - BioSpace biospace.com - March 15 at 11:35 PM
	ViewRay (VRAY) Announces Departure of Chief Operating Officer - StreetInsider.com streetinsider.com - March 15 at 6:35 PM
	ViewRay COO Shahriar Martin named CEO at Cordis - Cleveland - The Business Journals bizjournals.com - March 15 at 6:35 PM
	ViewRay - Seeking Alpha seekingalpha.com - March 15 at 6:35 PM

Date	Company	Brokerage	Action
3/1/2021	AxoGen	SVB Leerink	Boost Price Target
3/1/2021	AxoGen	Canaccord Genuity	Boost Price Target
1/12/2021	AxoGen	Cantor Fitzgerald	Boost Price Target
10/22/2020	AxoGen	Guggenheim	Initiated Coverage
8/5/2020	AxoGen	BTIG Research	Reiterated Rating
8/7/2019	AxoGen	JMP Securities	Lower Price Target
8/7/2019	AxoGen	William Blair	Downgrade
9/2/2020	Natus Medical	Raymond James	Reiterated Rating
3/29/2021	TransMedics Group	Cowen	Boost Price Target
3/9/2021	TransMedics Group	Morgan Stanley	Boost Price Target
3/2/2021	TransMedics Group	Oppenheimer	Boost Price Target
10/8/2020	TransMedics Group	JPMorgan Chase & Co.	Downgrade
2/25/2021	Semler Scientific	B. Riley	Boost Price Target
11/6/2020	Semler Scientific	Lake Street Capital	Boost Price Target
10/5/2018	Semler Scientific	Dougherty & Co	Initiated Coverage
1/12/2021	ViewRay	Piper Sandler	Boost Price Target
3/13/2020	ViewRay	Mizuho	Reiterated Rating
10/15/2019	ViewRay	Piper Jaffray Companies	Set Price Target

(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources